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1 Introduction
In 1982, the company Eli Lilly received approval
for the first recombinant protein, i.e. human insulin,
for therapeutic use in the EU. More than 30 years
later, in 2015, a total of 185 biotechnologically-derived
drugs has been approved (VFA, 2015). They are
applied in various therapeutic areas, such as oncol-
ogy (e.g., monoclonal antibodies against breast
cancer), haematology (e.g., erythropoietin or epo-
etin against anemia), bleeding disorder (e.g., Fac-
tor VIII) or immunology (e.g., interferon alfa).
These biotechnologically-derived drugs are called
“biopharmaceuticals” or “biologics”. The latter term
will be used in this article, following the nomen-
clature of de Mora (2015). As shown in table 1, bio-
logics differ from medicinal products that are chem-
ically synthesized such as acetylsalicylic acid, which
will further be referred to as “chemically-synthe-
sized drugs”, in a number of ways (Dingermann and
Zündorf, 2014; ProGenerika, 2014a, Schellekens,
2004).
Biologics are significantly larger than chemical-
ly-synthesized drugs. Their size can be up to sever-
al hundred kDa in the case of monoclonal antibod-
ies. Due to their size, they cannot be manufactured
by chemical synthesis but have to be produced by
using biotechnological processes in living cells. Bio-
logics are complex molecules with therapeutic effi-
ciency depending on their higher-order structure,
especially the tertiary structure of the protein, and
the pattern of post-translational modifications such
as glycosylation or disulfide bridges. Thus, biolog-
ics have to be administered parenterally as they
otherwise would undergo significant structural
modifications in the gastrointestinal tract. For exam-
ple, a protonation of basic amino acid side chains
in the acidic environment in the stomach would
lead to the denaturation of the protein and thus
nullifying the desired therapeutic effect. The inher-
ent structural complexity of biologics combined
with the high quality level required for intravenous
administration, is one of the key differences of this
class of medicinal products compared to chemical-
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Table 1 Comparison of biologics and chemically-synthesized drugs.
Biologics Chemically-synthesized drugs
Type of molecule and size Large polypeptide chains (molecular weight: usually more than 10 kDa)
Mostly small chemical molecules 
(molecular weight usually less than 1 kDa)
Production Biotechnological synthesis Chemical synthesis
Physico-chemical 
characteristics
Complex, heterogeneous and labile structure
(e.g., tertiary  structure is depending on pH) Well-defined, stable structure
Analytics Structure as well as purity difficult to determine due to structural complexitiy
Structure and purity can be determined
relatively easily
Biological impurities Elaborate measures required to preventviral/bacterial/fungal impurities Very rare
Immunogenicity Potentially immunogenic Very rare
Dosage form Usually parenteral (e.g., via intravenous injection of a solution)
Usually oral application
(e.g., pills)
ly-synthesized drugs. This is reflected by an elabo-
rate and expensive development process as well
as the high prices of biologics, which are in turn
increasing therapy costs. For example, the price for
five doses of Remicade® is reported to amount to
EUR 4,675 (Apotheke adhoc, 2015).
As the patents of originator products, i.e. the
biologics that have first entered the market, expired
or are about to expire, the market is now open for
generic producers to enter this seemingly attrac-
tive market. Generic manufacturers usually pro-
duce a molecular copy of the originator product
and sell it at a lower price. This is also very attrac-
tive for health insurance companies in order to
reduce the financial burden on the healthcare sys-
tem.
However, it is not possible to produce an exact
copy of the original molecule. Even minor differ-
ences in the manufacturing process will e.g. result
in a different glycosylation pattern of the product
and thus yield in a different molecule. The Euro-
pean Medical Agency (EMA) thus developed the
expression “biosimilar” in their 2005 guideline (EMA,
2005). A biosimilar is a medicinal product shown
to be essentially the same as the original product
but not identical. The term “biogeneric” is there-
fore not suitable for biologics and should not be
applied. In the context of this article, it is further
important to distinguish between first-wave and
second-wave biosimilars (Hinderer, 2012; Schellekens,
2015). The first refers to smaller and “simple” bio-
molecules such as insulin or the growth hormone
somatropin, which are produced in E. coli or yeast
cells and usually do not show post-translational
modifications. The second term refers to larger bio-
molecules such as monoclonal antibodies that
exhibit a much broader structural diversity and
which are usually produced in mammalian cells
giving way to different post-translational modifi-
cations. 
In this work, the status quo of the market for
biosimilars is analyzed along the structural frame-
work of a PEST analysis (P: political environment,
E: economic environment, S: social environment, T:
technological environment) with primary focus on
the following questions:
Political environment: How far developed and
reliable is the regulatory framework for the intro-
duction of biosimilars? What is required to obtain
marketing authorization for a biosimilar? Are
there companies that have successfully run
through the authorization process in the EU?
Economic environment: How large is the mar-
ket of biologics that have already lost or are los-
ing patent protection? How will the competi-
tive environment in the biosimilars market
evolve – and will there be a difference to the
“classical” chemically-synthesized generics? 
Social environment: What is the role of key stake-
holders such as health insurance companies,
physicians or patients in the biosimilars mar-
ket? What is their attitude towards biosimilars
and to what extent do they affect market
dynamics?
Technological environment: What are the key
competencies required in biosimilars develop-
ment, especially with respect to project man-
agement? To what extent are analytical tech-
niques (already) capable to demonstrate “sim-
ilarity” between a biosimilar and its reference
product?
Based on this status quo, an outlook on the
biosimilars market is established and management
implications for different types of market players
are discussed.
2 Methods
2.1 PEST analysis
The PEST analysis was mainly based on second-
ary research supplemented with primary research
where applicable and appropriate. Table 2 provides
an overview on the sources used.
2.2 Market outlook
In order to monitor the market dynamics of the
last years and to establish a sound database for a
market outlook, 234 peer-reviewed scientific arti-
cles and conference contributions (referred to as
“sources” in the following) containing the keyword
“biosimilar” were analyzed. Those sources were
selected by conducting a search for the keyword
“biosimilar*” either in the title or abstract of a pub-
lication within the timeframe from 2004 to 2015
in the scientific database Sciencedirect (Sciencedi-
rect, 2015). Each of the sources was classified in one
of the three categories “skeptical”, “neutral” and
“positive”, depending on its characteristic content.
The source was classified as “sceptical” when the
text rather questions the viability of biosimilars
and discusses mainly problems in the context of
biosimilars. A text is classified as “neutral” when it
does not generally question the viability of biosim-
ilars and discusses both problems and suggestions
for solutions. The source was classified as “posi-
tive" when the text acknowledges the potential of
biosimilars and discusses solutions rather than
highlighting problems.
3 Results
3.1 PEST analysis
3.1.1 Political perspective
The EU was the first region to establish regula-
tory guidelines for the authorization of biosimilars
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Dimension Topic
Methods and sources
Secondary research Primary research
Political
Regulatory framework  for biosimilars Peer-reviewed scientific literatureEU biosimilar guidelines -
Authorization process for biosimilars EU biosimilar guidelines -
Overview on approved biosimilars 
in the EU VFA data on authorized drugs in the EU -
Economic
Market potential
BCG/VFA annual report on biologics 
market
IMS Health presentation (Sheppard and 
Di Biase, 2014)
-
Market size Pro Generika data on biosimilars market -
Competitive environment
IMS Health presentation (Sheppard and 
Di Biase, 2014)
Company websites
-
Social
Stakeholder analysis: healthcare funds Peer-reviewed literature Expert interviews
Stakeholder analysis: physicians Peer-reviewed literature Expert interviews
Stakeholder analysis: patients Peer-reviewed literature -
Technological
Project management competencies Peer-reviewed literature -
Bioanalytical know-how Peer-reviewed literature -
Table 2 Overview on methods and sources applied in the PEST analysis.
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(EMA, 2005). These guidelines reflect the complex-
ity of biologics on a regulatory level as it requires
a substantial amount of pre-clinical and clinical
studies before obtaining marketing authorization
(figure 1). While pre-clinical studies are required in
order to confirm similarity on a molecular level,
clinical studies are required to confirm the thera-
peutic efficiency of the biosimilar.
The necessity of the clinical phase III in the devel-
opment of biosimilars is required due to the fact
that structural differences such as a different gly-
cosylation pattern in the biosimilar compared to
the original drug may affect the therapeutic effi-
ciency of the medicine. Companies planning to mar-
ket a biosimilar thus need to demonstrate that their
product is at least as effective as the original drug.
It is possible that once the effectivity of the biosim-
ilar is established for one indication, the results can
be extrapolated to other indications. For example,
the biosimilar monoclonal antibody infliximab was
approved in the EU in 2013 for all indications of the
originator product (Remicade®, Johnson & John-
son), including rheumatoid arthritis, psoriasis arthri-
tis, psoriasis, inflammatory bowel diseases and
ankylosing spondylitis (GaBiOnline, 2013). Howev-
er, in Canada, the same biosimilar was only approved
for autoimmune arthritis as an extrapolation of
the clinical data to inflammatory bowel diseases
was not granted (GaBiOnline, 2015a). Extrapolation
to other indications thus remains a subject of
debate, which is also underlined by the discussion
in the scientific community (Weise, 2014). The neces-
sity of the pre-clinical phase as well as the clinical
phase III in the biosimilar development marks the
major difference to chemically-synthesized gener-
ic drugs which are only required to demonstrate
their bioequivalence with the original drug in clin-
ical phase I. A comprehensive discussion on the pre-
clinical development of biosimilars can be found
in a recently published paper by Bui et al. (2015).
Additionally, after having obtained marketing
authorization, companies further need to imple-
ment a pharmacovigilance plan, i.e. further stud-
ies in order to rule out potential long-term nega-
tive side effects.
This different extent in pre-clinical and clinical
studies leads to significant higher development
costs for biosimilars which may reach up to EUR
200 mn, representing 20% of the development
costs of the original drug (ProGenerika, 2014b), com-
pared to the development of chemically-synthe-
sized generic drugs which require less than 1% of
the development costs of the original drug (Mell-
stedt, 2013). This also results in a lower price reduc-
tion compared to the original drug. Prices for biosim-
ilars are usually set 10 to 30% below the originator
Figure 1 Simplified comparison of the marketing authorization process for original pharmaceutical drugs, chemically-
synthesized generic drugs and biosimilars.
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price (Tsuruta et al., 2015), but there is one exam-
ple of a biosimilar that was introduced at a 72%
discount in Norway (GaBiOnline, 2015b). The mar-
ket price for chemically-synthesized generic drugs
are usually more than 80% below the price of the
original product. On the other hand, both chemi-
cally-synthesized generic drugs and biosimilars do
not need to run through the “drug discovery” phase
as the therapeutic target of the medicinal product
is already known. The clinical phase II is also not
required as the dosage of the biosimilar is the same
as for the original product.
As shown in table 3, a total of 18 biosimilars
received marketing authorization from the EMA
between 2006 and 2014 (VFA, 2015). This underlines
the applicability of the EMA guidelines.
One should note that the list of biosimilars in
table 3 also contains the monoclonal antibody inflix-
imab, which received approval. This is remarkable
as monoclonal antibodies represent the most com-
plex biologics and their development as biosimi-
lar was seen very skeptical some years ago (Schnei-
der and Kalinke, 2008). Given the fact that the devel-
opment of biosimilar monoclonal antibodies is
nevertheless possible, it underlines the broad appli-
cability of the EMA framework.
After the establishment of biosimilar guidelines
in the EU, more than 30 countries worldwide have
also set up their own guidelines (Heinemann et al.,
2015). These countries comprise large pharmaceu-
tical markets such as Japan, where guidelines were
established in 2008, for Canada in 2009, for the US
in 2010 and for India in 2011, respectively. In China,
regulatory guidelines are currently in the evolution
process (Heinemann et al., 2015). This evolving reg-
ulatory environment for biosimilars will continue
to give companies a reliable framework for their
development process.
3.1.2 Economic perspective
The market potential for biosimilars is prima-
rily driven by the market growth of biologics which
is in turn determined both by the growing num-
ber of biologics on the market as well as their high
price. The market of biologics has grown signifi-
cantly in recent years (figure 2). In 2006, biophar-
maceuticals already represented 12% of the Ger-
man pharmaceuticals market value – by 2014, the
market share of biopharmaceuticals had raised to
22%. During this period, biopharmaceuticals grew
with a compound annual growth rate (CAGR) of
12%, whereas chemically-synthesized drugs rather
stagnated with a 1% CAGR as shown in figure 2
(BCG, 2006-2015).
Furthermore, more than ten blockbuster bio-
Table 3 Overview of biosimilars that successfully obtained marketing authorization in the EU since 2006 (VFA, 2015).
Product Company Active pharmaceutical ingredient Marketing authorization
Omnitrope® Sandoz Somatropin 2006
Epoetin alfa Hexal® Hexal Epoetin alfa 2007
Abseamed® Medice Epoetin alfa 2007
Binocrit® Sandoz Epoetin alfa 2007
Retacrit® Hospira Epoetin zeta 2007
Silapo® Stada Epoetin zeta 2007
Ratiograstim® Ratiopharm Filgrastim 2008
Tevagrastim® Teva Filgrastim 2008
Filgrastim Hexal® Hexal Filgrastim 2009
Zarzio® Sandoz Filgrastim 2009
Nivestim® Hospira Filgrastim 2010
Grastofil® Apotex Filgrastim 2013
Ovaleap® Teva Follitropin alfa 2013
Remsima® Celltrion Infliximab 2013
Inflectra® Hospira Infliximab 2013
Accofil® Accord Filgrastim 2014
Bemfola® Finox Biotech Follitropin alfa 2014
Abasaglar® Eli Lilly Insulin glargin 2014
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logics, i.e. drugs with annual sales of more than
EUR 1bn, will lose their patent protection in the
period from 2013 to 2019 (Sheppard and Di Biase,
2014) as demonstrated in table 4.
This underlines the market attractiveness from
a sales perspective. As shown in section 3.1.1, com-
panies already start to enter this market. Howev-
er, as can be seen from figure 3, biosimilars demon-
strate only a limited market penetration so far (Pro-
Generika, 2015).
Currently, biosimilars containing infliximab,
somatropin, epoetin or filgrastim only represent
less than one fifth of the German market for bio-
logics that have already lost patent protection.
However, there are significant differences in the
market penetration depending on the product.
With 8% market penetration, the market for the
monoclonal antibody infliximab currently shows
the lowest values. However, this biosimilar has only
been introduced on the market in February 2015
and reached about 18% market share in October
2015 (ProGenerika, 2015). It remains to be seen
whether this share can be increased in the upcom-
ing months. In the case of somatropin, only one
biosimilar player, i.e. Sandoz, is competing against
an oligopoly of six companies producing the orig-
inal product: Pfizer, Novo Nordisk, Merck, Eli Lilly,
Ferring and Ipsen Pharma. This competitive envi-
ronment makes market penetration for the biosim-
ilar drug difficult to achieve. Competition based on
price alone will be difficult due to the low price
reduction of the biosimilar compared to the origi-
nal product as discussed above. Epoetin biosimi-
lars have achieved a somewhat larger market pen-
etration, mainly due to the fact that epoetin ther-
apies are mostly short-term therapies which makes
it easier to switch from the original product to a
biosimilar. In this context, it is important to note
that a biosimilar is usually applied from the begin-
ning of a therapy and physicians are reluctant to
substitute an original biologic during an ongoing
therapy. Filgrastim biosimilars have achieved the
largest market penetration, probably due to the
fact that seven biosimilar players have received
marketing authorization (see table 3), whereas there
is only one company on the market, Amgen, who
markets the original product. However, given the
relatively small size of the filgrastim market, this
does not change the overall picture of a currently
low market penetration of biosimilars.
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Figure 2 Market size and growth of the German pharmaceutical market in the period 2006–2014.
© 2016 Institute of Business Administration 
Understanding the market dynamics of biosimilars
Journal of Business Chemistry 2016, 13 (1) 39
Table 4 Original blockbuster biologics that lose their patent protection in the period 2013–2019.
Year Original biologic Company Global sales 2014 (€ bn)
2013 Mabthera Roche 6.0
2014
Novomix Novo Nordisk 5.9
Herceptin Roche 5.0
2015
Remicade Johnson&Johnson 7.4
Enbrel Pfizer 7.8
Lantus Sanofi 8.6
Avonex Biogen Idec 5.2
Neulasta Amgen 4.2
2016 Lucentis Novartis 4.2
2018 Humira Abbvie 10.2
2019 Avastin Roche 5.5
Figure 3 Market penetration of biosimilars in four selected biologics market segments.
Potential biosimilars
market Jan – Sep 2015 Infliximab Somatropin Epoetin Filgrastim
Biosimilars Original biologics
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The competitive environment in the biosimi-
lars market is shaped by at least three different
types of companies:
Traditional generics manufacturer (e.g., Teva,
Sandoz, Stada),
Large pharmaceutical companies (e.g., Eli Lilly),
New market entrants (e.g., Celltrion).
Traditional generics companies were the main
driving force behind the first wave of biosimilars,
such as somatropin, filgrastim and epoetin. Their
development is less complex (and probably less
cost intensive) compared to second-wave biosim-
ilars, so that the entrance of some traditional gener-
ics player is not surprising. However, so far there
have only been attempts but no classical generics
company has successfully developed a second-wave
biosimilar, which require more initial investments
and bear a higher risk. The company Stada invest-
ed in a development program for the biosimilar
trastuzumab, a monoclonal antibody, but canceled
the project in 2010 and further decided to follow
an in-licensing strategy (Stada, 2011). The compa-
ny Teva, together in a joint venture with the Swiss
company Lonza,  stopped clinical trials on their
biosimilar rituximab in 2012 (Biosimilar News, 2012).
Biosimilars also present an (additional) attrac-
tive market for large pharmaceutical companies
(Ledford, 2010). As the price of a biosimilar is usu-
ally at least 70% of the originator price, it is attrac-
tive for these companies to invest in development
programs of biosimilars as well. One significant
advantage compared to the development of novel
pharmaceutical drugs is the fact that the pharma-
ceutical target is already known, which means that
there is no need for cost-intensive research and
development in the early phase of drug develop-
ment and a higher probability of success. Addition-
ally, large pharmaceutical companies benefit from
their development expertise and financial strength
to approach the development of second-wave
biosimilars. Indeed, looking at the development
pipeline of biosimilar monoclonal antibodies, one
can observe that large pharmaceutical companies
such as Boehringer Ingelheim, Pfizer and Merck are
currently trying to enter this market (ProGenerika,
2014b).
Another strategy for established large biophar-
maceutical companies like Amgen or Sanofi is the
development of so-called “biobetters”, i.e. improved
versions of the original product that again receive
patent protection (Casey, 2015). Examples would
be insulin glargin (e.g., Sanofi’s human insulin ana-
logue Lantus®) or a PEGylated form of filgrastim
(e.g., Amgen’s Neulasta®). The development of a
biobetter can be interpreted as a strategy of orig-
inal producers pursuing patent extension and will
not be discussed in detail here as it was discussed
elsewhere (Casey, 2015).
Most interestingly, there are also new market
entrants that are stirring up the competitive envi-
ronment. One of the most intriguing case exam-
ples is the company Celltrion (South Korea). Found-
ed in 2002, the company received EU approval for
the monoclonal antibody infliximab (product: Rem-
sima) in 2013 and started to enter the market in
2015 (after patent expiration of the original prod-
uct). Celltrion can be classified as a so-called “emerg-
ing market player”, a company that first focuses on
a certain number of regional markets (e.g., India)
before attempting to enter the highly regulated
pharmaceutical markets in the EU and the USA
(Sheppard and Di Biase, 2014).
3.1.3 Social environment
In order to evaluate the social environment,
three different stakeholders involved in the mar-
ket acceptance of biosimilars are examined:
Health insurance companies as they are respon-
sible for refinancing the therapies,
Physicians as they decide about the application
of a biosimilar versus the original biologic,
Patients as they are in the end the market par-
ticipants who receive treatment with the biosim-
ilar.
Pharmacies were not included in the analysis
as they are not involved in the decision process
about whether a biosimilar or an original drug
should be used. This is a sharp contrast to chemi-
cally-synthesized generics, where automatic sub-
stitution at the pharmacy gives the pharmacist a
completely different role.
Health insurance companies are generally open
towards biosimilars as they represent a means to
reduce the financial burden on healthcare systems.
Even if the price reduction is usually only in the
order of 10 to 30% compared to the original bio-
logic drug, this still represents huge potential sav-
ings for the healthcare system. In order to create
incentives for physicians to favor biosimilars dur-
ing the prescription of drugs, healthcare funds intro-
duced target agreements in some German regions
(ProGenerika, 2014a). For example, the Association
of Statutory Health Insurance Physicians
(Kassenärztliche Vereinigung) of the federal state
Bremen included specific prescription target quo-
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tas in its annual agreement with the healthcare
insurance companies (KV Bremen, 2015). As a result,
Bremen belonged to the federal states in Germany
with the highest prescription quota for biosimilars
(ProGenerika, 2015).
The typical discount contracts that are usually
applied after patent expiration of a drug are not
seen as an instrument to improve the usage for
biosimilars by healthcare insurance companies.
Given the high development costs for biosimilars,
discount contracts rather favor the original pro-
ducer who already had the opportunity to earn
their return on investment. For a biosimilar pro-
ducer, discount contracts would represent a high-
er risk as they would be trapped between earning
their investment and realizing a low price to be
attractive for health insurance companies. 
Physicians are the most important stakehold-
er group as they are responsible for prescribing the
biosimilars. However, they are currently rather skep-
tical towards biosimilars as they are not sufficient-
ly informed. In particular, they are concerned about
the pharmaceutical quality of biosimilars, their
safety (immunogenicity potential), efficacy (extrap-
olation in clinical studies), and interchangeability
with the originator product (Cuadrado et al., 2013;
Lie et al., 2015; Mellstedt, 2013; Rompas et al., 2015;
Weise et al., 2012), which is also underlined by a
survey among physicians (N=307) with focus on
inflammatory bowel diseases (Danese et al, 2014).
These results are corroborated by selected expert
interviews (N = 6) that were conducted in the course
of this study. Most of the interviewees (N=5) have
not yet heard of biosimilars. One physician (nephrol-
ogist) who had experience with epoetin, stated:
“Production, quality, immunogenicity and effi-
cacy of biosimilars are not sufficiently transpar-
ent. Clinical studies are extrapolated by using
the data of the reference product, which is not
suitable.”
It is interesting to note that such skepticism
remains although biosimilars have to run through
a thorough authorization process as outlined in
section 3.1.1, and that they, to the best of our knowl-
edge, did not yet show any adverse effects. How-
ever, in order for biosimilars to be successful on the
market, companies also have to think about how
to better inform physicians about the therapeutic
advantages of biosimilars.
Patients, on the other hand, are nowadays bet-
ter aware about their diseases and the therapeu-
tic options. For chronological diseases such as can-
cer, patients seem to be rather skeptical about
changing from an established original biologic to
a biosimilar. They also think critical about the expres-
sion “biosimilar”, as the word “similar” implies not
getting the same drug. For short-term therapies
such as epoetin treatment, on the contrary, substi-
tution of the original product with a biosimilar
seems less problematic.
3.1.4 Technological
Concerning the technological perspective, the
literature review reveals two major topics. The first
of them, the so-called quality-by-design (QbD)
approach, is receiving increased attention as an
approach to project management in biosimilar
development and production. The QbD approach
was first introduced by Juran (1992) and has been
adopted by the U.S. Food and Drug Administration
(FDA) for the development of pharmaceutical prod-
ucts (FDA, 2007). The QbD approach has also been
explicitly discussed for biologics (Rathore, 2009;
Scott, 2011). Essentially, the QbD approach aims at
a thorough understanding as well as control of the
potential influencing variables in the manufactur-
ing process of a pharmaceutical drug from the very
beginning. Thereby, the risks associated with the
development process of a pharmaceutical drug,
such as process changes (Schiestl, 2011) or variabil-
ity of (biological) raw material quality (Rathore,
2009), should be better understood and thus already
mitigated during the development phase, e.g. upon
planning of the manufacturing process. The QbD
approach is also reflected by the proverb “the
process is the product” that is often coined in the
context of biosimilars. It gives companies a high-
er flexibility in designing a manufacturing process
for biosimilars and reflects the inherent complex-
ity of biomolecules on a project management level
as it provides companies with the flexibility to
decide how to best obtain the end product. On the
other hand, this flexibility may come at the cost of
higher uncertainty for companies as a large num-
ber of process parameters have to be taken into
account from the very beginning of a biosimilar
development project. 
The second important topic is the question of
how to proof similarity of a biosimilar to the refer-
ence product. Again, given the large molecular size
and the inherent complexity of biologics, it is obvi-
ous that a large array of state-of-the-art bioana-
lytical tools is required to address this question.
Due to the progress in analytical science, there are
now many different analytical methods available
to analyze biosimilars (Kálmán-Szerekes et al., 2012;
Tsuruta et al., 2015). Especially mass spectrometry
has proven as an invaluable tool to analyze struc-
tural similarity, as has been highlighted e.g. by stud-
ies of epoetin biosimilars (Harazono et al., 2013) as
well as complex monoclonal antibodies (Beck et
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al., 2013). Even batch-to-batch structural changes
or structural alterations upon variation of the man-
ufacturing process can be monitored (Kálmán-
Szerekes et al., 2012). From the perspective of inno-
vation management, it is interesting to note that
the progress of the (bio)analytical science seems
to be a necessary prerequisite in order to capture
the market potential of biosimilars, which is in line
with the assumption of some experts that analyt-
ical science is a key driver of innovation in the chem-
ical sciences (Franz, 2013).
3.1.5 Summary of PEST analysis
The summary of the PEST analysis of the biosim-
ilars market is shown in figure 4.
The analysis shows that the market is econom-
ically attractive and that both the technological
means to address this market as well as the regu-
latory environment that ensures a framework in
which companies can operate to capture this mar-
ket are at hand. However, the regulatory environ-
ment must be flexible enough to adapt to techno-
logical progress (Huzair and Kale, 2015). The chal-
lenges to successfully develop a biosimilar may still
be high but the huge market opportunity seems
to make investments worthwhile, which is in line
with previous findings (Blackstone and Fuhr, 2013).
The current major bottleneck for the biosimilar
market development seems to be an overall skep-
tical attitude of physicians as they do not feel suf-
ficiently informed about biosimilars and are rather
reluctant to prescribe those drugs.
3.2 Market outlook
Due to the factors discussed in the previous sec-
tion, the biosimilars market does currently not cap-
ture its full market potential. However, chemical-
ly-synthesized generics also faced a similar situa-
tion 20 years ago. In 1990, only about 30% of the
potential generics market were actually served by
generics (the remaining 70% were occupied by orig-
inator drugs) (BPI, 2000; PhRMA, 2015). Interviews
both with a market expert of the association Pro-
Generika e.V. and a leading German health insur-
ance company corroborated this finding. Accord-
ing to these interviews, the current market situa-
Figure 4 Summary of the key findings of the PEST analysis for the biosimilars market (“+” indicates a positive influence on 
the biosimilars market, “-“ indicates a negative influence on the biosimilars market, “?” indicates that the factor 
can have both a positive or a negative influence).
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tion of biosimilars can be interpreted as “starting
difficulties” of an innovative market. However, it is
not clear whether the biosimilar market will take
a similar development as the market for chemical-
ly-synthesized generics. Given the complexity of
the product and the lower number of competitors,
no final conclusion concerning the comparability
of these two markets can be drawn so far.
In order to better understand the perspective
of different stakeholders on biosimilars in recent
years, 234 peer-reviewed scientific articles and con-
ference contributions were analyzed. The analysis
revealed that the perspective of the scientific com-
munity towards biosimilars changed from a rather
skeptical evaluation 10 years ago to a rather posi-
tive assessment in 2015 (figure 5).
In the same period, an increasing number of
countries developed guidelines on biosimilars
(Heinemann et al., 2015) and significant progress
in bioanalytics was made. In 2007, testing for sim-
ilarity and comparability was still seen as “causes
of concern” (Roger and Mikhael, 2007), whereas
eight years later, Tsuruta et al. (2015) argue that
“…improved analytical methods [...] allow for the
detection of even small changes […] between lots
of the reference products currently on the market”
(Tsuruta et al., 2015).
Finally, another important aspect when dis-
cussing the market outlook for biosimilars, is the
demographic change in developed countries. Fac-
ing a rising life expectancy and a growing average
age, access to high quality medicine without com-
promising the benefits of national healthcare sys-
tems already is and will become a major issue for
healthcare politics. Biosimilars can play a crucial
role in this context.
4 Concluding remarks
Biosimilars have successfully entered the health-
care market and broadened the access to afford-
able high quality medicinal products. An estab-
lished regulatory environment secures the frame-
work for companies seeking to invest in this dynam-
ic market. The current skeptical attitude of
physicians and patients should be addressed by
better informing these stakeholder groups about
biosimilars, e.g. by teaching medical students at
universities about biosimilars in order to improve
the attitude of physicians or by information
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Figure 5 Assessment of the attitude towards biosimilars within the scientific literature based on the analysis of peer-
reviewed articles and conference contributions (N=234).
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brochures about biosimilars in order to improve
the attitude of patients. Based on the comparison
with chemically-synthesized generics and the
changed attitude of the scientific world towards
biosimilars, the market share of biosimilars in the
market for biologics that already lost patent pro-
tection is expected to increase in future. The mar-
ket is thus attractive for companies thinking about
to enter this innovative environment.
The implication for the management depends
on the type of company. For traditional generic com-
panies, development of a second-wave biosimilar
does not seem to be attractive, given the high
upfront investments and the high risk. For them,
seeking alliances with larger biosimilar companies
would probably yield more success, e.g. if they focus
on distribution, their core competency, and in-license
the biosimilar from a company that focuses on
biosimilar development and does not have market
access. Potential partners could be, e.g., market
entrants from foreign markets.
For big pharmaceutical companies, biosimilars
seem to be an attractive option to fill their pipeline
and to leverage their development expertise as well
as their financial strength. As development of a
biosimilar requires much of the expertise of new
drug development, big pharma companies should
be in a good starting position to address this mar-
ket.
For new market entrants, the hurdles are high:
regulatory know-how, expertise in quality-by-design
project management and financial strength. How-
ever, as the case of Celltrion shows, given the right
strategy and financial support, also those compa-
nies can enter the market.
The biosimilars market will probably develop
towards an oligopolistic market, as also found in
other studies (Declerck and Simoens, 2012; Rompas
et al., 2015). The competitive environment will be
shaped by a mix of non-classical competitors such
as big pharmaceutical companies and new market
entrants from foreign markets as well as a small
number of classical generic players in the first-wave
biosimilar market. Product competition in this mar-
ket will rather occur between the biosimilar and
the originator drug than between different biosim-
ilar versions of the drug as can be observed for
chemically-synthesized generics, which has also
been described by Carlson (2009). But even if the
competitive environment will be characterized by
a lower number of players compared to the chem-
ically-synthesized generics market, the financial
burden on the healthcare system will nonetheless
be reduced, which will be a major driver of the
biosimilars market in the long run. Biosimilars will
thus continue to become an integral part of the
pharmaceutical portfolio in the future. The ques-
tion will no longer be “if” but rather “when” this
dynamic market will see its breakthrough.
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